ERAS Company Profile and Key Details

ERAS has shown sold momentum, gaining 57.46% over the past week and 305.37% over the past quarter, though year-to-date performance is up 163.71%. Short-term trend indicators are bearishly aligned (SMA20 12.64%, SMA50 60.29%, SMA200 282.56%). The stock’s 14-day RSI is 76.12 (overbought), while the ATR of 0.78 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -4.23% below its high and over 1243.56% above its low. Average 10-day trading volume of 3.44 million shares is below the 3-month average of 4.97 million, indicating normal recent market interest.

Erasca, Inc. has 347.13 million shares outstanding. The public float is 247.63 million shares, elevated short interest at 9.82% of float. This equals 30.77 million shares. The short ratio is 4.99 days. Institutional investors hold 94.48% of the float. Insiders own 9.69%. Lim Jonathan E holds 12.90 million shares, Chen Bihua has 10.81 million shares and Casdin Alexander W. has 573.97 thousand shares. Over the past six months, insider transactions show net selling. They sold 100.00 thousand shares across 2 transactions.

Erasca, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.09. This means the shares are trading above this model’s fair value.

Erasca, Inc. (NASDAQ:ERAS) closed at $18.27 USD, losing -$0.35 (-1.88%) from the previous close of $18.62. The stock is currently mid-range between its 52-week high and low $1.33 and $24.28. With a market capitalization of about $6.34 billion, Erasca, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.67). Key stats such as the average daily volume over the past year has been around 5.11 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Erasca, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jonathan E. Lim, the company employs approximately 103 people and listed since July 16, 2021. Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway.

Erasca, Inc. generated EPS of -$0.45 over the past year. Five-year average earnings growth is -46.86%. Wall Street analysts project EPS growth of 8.46% annually over the next five years. The latest quarter delivered EPS of -$0.60. The next quarter is forecast at -$0.11. Next year's EPS is expected at -$14.35. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 8 Buy ratings, 4 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $30.00 to $1.00. The high target offers 64.2% upside. The low target suggests -94.53% downside. The mean target is $14.60. This offers -20.09% upside. Erasca, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 475.32%. The prior quarter beat by -9.09%. Over the last six quarters, Apple has recorded several small beats. These include -8.33% in May 13, 2025.

Our AI price prediction model suggests that Erasca, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.07%, with price expected at $17.71 by August 19, 2026, within a range of $16.75 to $18.57 3-Month Outlook: Projected rise of 69.9%, reaching $31.04 by November 03, 2026, with a range of $30.74 to $31.35. 1-Year Outlook: Projected gain of 14.72%, with price at $20.96 by August 05, 2027, within a range of $19.44 to $22.60.

Erasca, Inc. (NASDAQ:ERAS) shares are up 163.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Erasca, Inc. trading at a premium to the broader market with a P/E of -19.72. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $11.24, suggesting -38.48% downside. Our AI forecast model points to short-term weakness (-3.07% over two weeks), a medium-term rise (69.9% over three months), and a longer-term gain (14.72% over one year), with expected trading ranges indicating moderate volatility.

Erasca, Inc. trades at a P/E ratio of -19.72, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 14.18 reflecting a rich premium to book value. The P/FCF stands at -69.68, also below market averages. Compared to sector medians, Erasca, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.